European Medicines Agency (EMEA) is a decentralized body of the European Union with headquarters in London.
'The EMEA began its activities in 1995, when the European system for authorizing medicinal products was introduced, providing for a centralized and a mutual recognition procedure. The EMEA has a role in both, but is primarily involved in the centralized procedure. Where the centralized procedure is used, companies submit one single marketing authorization application to the EMEA. A single evaluation is carried out through the Committee for Medicinal Products for Human Use (CHMP) or Committee for Medicinal Products for Veterinary Use (CVMP). If the relevant Committee concludes that quality, safety and efficacy of the medicinal product is sufficiently proven, it adopts a positive opinion. This is sent to the Commission to be transformed into a single market authorization valid for the whole of the European Union.'
'Its main responsibility is the protection and promotion of public and animal health, through the evaluation and supervision of medicines for human and veterinary use. The EMEA coordinates the evaluation and supervision of medicinal products throughout the European Union. The Agency brings together the scientific resources of the 25 EU Member States in a network of 42 national competent authorities. It cooperates closely with international partners, reinforcing the EU contribution to global harmonization.'

(FDA) An agency of the US federal government established by Congress in 1912 and presently part of the US Department of Health and Human Services. The FDA gives classifications of medical devices according to potential risks and controls the safety of marketed drugs.
For more details please visit the FDA's 'Our Mission and Mandate'.

See also Class I II III Devices and Phase 1 2 3 4 Drug Trials.

The France-based Guerbet Group is highly specialized in contrast media for medical imaging. Its strategic goal is to be a key player in this market. Guerbet Group produces products for x-ray imaging, MRI, ultrasound imaging and imaging through radioactive tracers.

[This entry is marked for removal.]

As a full-line supplier of medical imaging equipment in Japan, Hitachi Medical Corporation (HMC) founded HMSA 1989 to provide a direct link to the U.S. marketplace. HMSA is responsible for the sales, marketing and service of all Hitachi Open MRI, PET/CT, Ultrasound, and Computed Tomography products in the United States.

In December 2019 Japan's Fujifilm announced the acquisition of Hitachi's diagnostic imaging business for 179 billion yen ($1.63 billion). This includes Hitachi’s CT, MRI, X-ray, and ultrasound imaging operations, also its electronic health record business. Fujifilm expects the deal to close in July 2020 subject to regulatory clearances.

(IAEA) The IAEA is an independent international organization related to the United Nations system today, founded in 1957 ('Atoms for Peace' Agency) as part of the United Nations family. Its mission is to promote and supervise worldwide safe, secure and peaceful nuclear technologies. The IAEA's three main areas of work are 'Safety and Security', 'Science and Technology', and 'Safeguards and Verification'.